Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Health Innovators – Amy Abernethy and Jennifer Goldsack Part One

Grünenthal takes non-opioid pain drug resiniferatoxin into phase 3

Fuelling the efficiency of drug development through sensor data integration

Dr B raises $8m for telehealth service to deliver COVID antivirals

CSL preps filings for once-monthly antibody for HAE

alimera

NICE1

NICE backs Alimera’s three-year uveitis implant

Phil Taylor alimera, NICE, ophthalmology, Rare diseases 0 Comment

An implant developed by Alimera Sciences has been recommended by NICE to treat an inflammatory eye disease that

X

NICE backs Alimera’s three-year uveitis implant

https://pharmaphorum.com/news/nice-backs-alimeras-three-year-uveitis-implant/

Ophthalmic Drugs 2018

News/ Partner content/ Press releases

Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 2018

Pavan Solanki alimera, elasmogen, ophthalmic, ophthalmology, Spark Therapeutics 0 Comment

Ophthalmic Drugs Conference London

X

Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 2018

https://pharmaphorum.com/partner-content/your-latest-ophthalmology-news-for-smis-ophthalmic-drugs-2018/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

End of the line for Sanofi's SERD amcenestrant as it fails first-line trial
GSK gets June 2023 FDA decision date for momelotinib
bluebird unveils $2.8m price for gene therapy Zynteglo on FDA approval
First Zantac cancer case dropped before trial, without settlement
Astellas files menopause drug fezolinetant in US, setting up Feb verdict

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com